Study Shows Telithromycin Superior to Standard Antibiotic Therapy for CAP
Data from the community-acquired pneumonia (CAP) outcome in high bacterial resistance areas (COBRA) study, a randomized clinical superiority trial, showed that the clinical efficacy of telithromycin (marketed as KETEK) in outpatients with CAP is superior to that of local standard first-line oral antibiotic therapy in areas with a high prevalence of penicillin or macrolide-resistant Streptococcus pneumonia.
The clinical cure rate with telithromycin was 7.2 percent higher than the overall clinical cure rate with comparator antibiotics. The COBRA study is a Phase IV clinical trial designed to compare the efficacy and safety of telithromycin to other standard, single agent antibiotics, such as B-lactams, cephalosporins, macrolides and quinolones, in outpatients with mild-to-moderate CAP in areas with a high prevalence of penicillin and erythromycin-resistant S. pneumoniae isolates. The study enrolled 505 patients from Italy, Spain, Taiwan, Korea, Hong Kong, Hungary, Thailand, South Africa, Singapore, Tunisia, and Greece and was completed in June 2004.
Upcoming Events
-
07May
-
14May
-
30May